Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66,019 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH. Park KH, et al. Among authors: park ih, park yh, park jh, park s. Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6. Support Care Cancer. 2017. PMID: 27709313 Clinical Trial.
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S, Lee MH, Seong M, Kim ST, Kang JH, Cho BC, Lee KH, Cho EK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Park S, et al. Among authors: park k. Ann Oncol. 2020 Oct;31(10):1397-1404. doi: 10.1016/j.annonc.2020.06.017. Epub 2020 Jul 5. Ann Oncol. 2020. PMID: 32634610 Free article. Clinical Trial.
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study.
Park S, Sun JM, Choi YL, Oh D, Kim HK, Lee T, Chi SA, Lee SH, Choi YS, Jung SH, Ahn MJ, Ahn YC, Park K, Shim YM. Park S, et al. Among authors: park k. ESMO Open. 2022 Feb;7(1):100385. doi: 10.1016/j.esmoop.2022.100385. Epub 2022 Feb 12. ESMO Open. 2022. PMID: 35158205 Free PMC article. Clinical Trial.
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. Park KH, et al. Among authors: park ih, park yh, park jh, park s. Invest New Drugs. 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16. Invest New Drugs. 2013. PMID: 23677653 Clinical Trial.
Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype.
Jang JE, Min YH, Yoon J, Kim I, Lee JH, Jung CW, Shin HJ, Lee WS, Lee JH, Hong DS, Kim HJ, Kim HJ, Park S, Lee KH, Jang JH, Chung JS, Lee SM, Park J, Park SK, Ahn JS, Min WS, Cheong JW; Korean Society of Hematology AML/MDS Working Party. Jang JE, et al. Among authors: park s, park sk, park j. Blood Cancer J. 2015 Oct 16;5(10):e358. doi: 10.1038/bcj.2015.84. Blood Cancer J. 2015. PMID: 26473530 Free PMC article.
66,019 results
You have reached the last available page of results. Please see the User Guide for more information.